Tomohiro Tanaka
Kurume University(JP)Tohoku University(JP)Kagawa Prefectural Central Hospital(JP)Niigata University(JP)
Publications by Year
Research Areas
Chemokine receptors and signaling, Immunotherapy and Immune Responses, Monoclonal and Polyclonal Antibodies Research, T-cell and B-cell Immunology, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial(2017)902 cited
- → Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study(2014)689 cited
- → CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study(2013)576 cited
- → Bivalent Ligands of CXCR4 with Rigid Linkers for Elucidation of the Dimerization State in Cells(2010)77 cited
- → Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia(2012)73 cited
- → Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive -positive non-small cell lung cancer ( NSCLC): Primary results from the J-ALEX study.